Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study

In this observational study (n=209 867 each arm), short term use of SGLT2 inhibitors were associated with decreased risk of cardiovascular events compared with use of DPP-4 inhibitors (incidence rate per 1000 person years: 11.4 v 16.5; HR 0.76, 95% CI, 0.69 to 0.84).

Source:

British Medical Journal